UBS Group Downgrades Harmony Biosciences (NASDAQ:HRMY) to Neutral

Harmony Biosciences (NASDAQ:HRMY) was downgraded by UBS Group from a “buy” rating to a “neutral” rating in a research note issued on Wednesday, MarketBeat reports. They presently have a $46.00 target price on the stock, up from their previous target price of $43.00. UBS Group’s target price points to a potential upside of 28.31% from the stock’s current price.

Several other equities analysts have also weighed in on HRMY. Wall Street Zen raised shares of Harmony Biosciences from a “hold” rating to a “buy” rating in a research report on Saturday, December 13th. HC Wainwright reissued a “buy” rating on shares of Harmony Biosciences in a report on Wednesday, December 3rd. Weiss Ratings restated a “hold (c)” rating on shares of Harmony Biosciences in a research report on Monday, December 29th. Zacks Research raised Harmony Biosciences from a “hold” rating to a “strong-buy” rating in a research report on Thursday, January 22nd. Finally, Mizuho increased their target price on Harmony Biosciences from $39.00 to $46.00 and gave the stock an “outperform” rating in a research note on Monday, December 1st. Two analysts have rated the stock with a Strong Buy rating, six have issued a Buy rating and three have assigned a Hold rating to the company. Based on data from MarketBeat, Harmony Biosciences has a consensus rating of “Moderate Buy” and an average price target of $45.63.

Harmony Biosciences Stock Performance

Shares of NASDAQ HRMY opened at $35.85 on Wednesday. The company has a current ratio of 3.75, a quick ratio of 3.72 and a debt-to-equity ratio of 0.18. The company has a market capitalization of $2.06 billion, a P/E ratio of 11.27, a P/E/G ratio of 0.34 and a beta of 0.84. Harmony Biosciences has a 12 month low of $25.52 and a 12 month high of $40.87. The stock has a 50 day moving average of $37.61 and a 200-day moving average of $34.32.

Insider Activity at Harmony Biosciences

In other Harmony Biosciences news, CFO Sandip Kapadia sold 3,746 shares of Harmony Biosciences stock in a transaction on Monday, January 26th. The stock was sold at an average price of $37.15, for a total value of $139,163.90. Following the completion of the transaction, the chief financial officer directly owned 24,521 shares of the company’s stock, valued at $910,955.15. The trade was a 13.25% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, CEO Jeffrey M. Dayno sold 25,933 shares of the company’s stock in a transaction on Friday, December 12th. The shares were sold at an average price of $40.11, for a total value of $1,040,172.63. The SEC filing for this sale provides additional information. Over the last quarter, insiders sold 50,640 shares of company stock valued at $1,932,256. 23.60% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of HRMY. Amundi increased its holdings in Harmony Biosciences by 115.6% in the 1st quarter. Amundi now owns 39,668 shares of the company’s stock valued at $1,229,000 after buying an additional 21,266 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. boosted its position in shares of Harmony Biosciences by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 22,651 shares of the company’s stock worth $752,000 after acquiring an additional 984 shares in the last quarter. Empowered Funds LLC acquired a new stake in shares of Harmony Biosciences during the 1st quarter worth approximately $2,330,000. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in Harmony Biosciences by 53.0% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 95,389 shares of the company’s stock valued at $3,166,000 after acquiring an additional 33,058 shares during the last quarter. Finally, KLP Kapitalforvaltning AS raised its position in Harmony Biosciences by 12.2% during the second quarter. KLP Kapitalforvaltning AS now owns 25,800 shares of the company’s stock valued at $815,000 after purchasing an additional 2,800 shares in the last quarter. Institutional investors and hedge funds own 86.23% of the company’s stock.

Key Headlines Impacting Harmony Biosciences

Here are the key news stories impacting Harmony Biosciences this week:

• Positive Sentiment: Several analyst notes and consensus price-targets point to meaningful upside (Zacks highlights an average analyst-implied upside of ~27%), supporting a bullish thesis around earnings revisions and valuation upside. Wall Street Analysts Believe Harmony Biosciences (HRMY) Could Rally
• Positive Sentiment: Coverage pieces are highlighting growing analyst optimism and valuation support, which can underpin a recovery if upcoming fundamentals meet expectations. Assessing Harmony Biosciences (HRMY) Valuation
• Neutral Sentiment: Analyst commentary and comparative valuation articles continue to circulate (e.g., Zacks pieces comparing HRMY to peers and questioning current valuation), providing background but not a single clear catalyst. HRMY vs. ARGX Is Harmony Biosciences (HRMY) Stock Undervalued?
• Neutral Sentiment: Short-interest reports in recent entries show anomalous “0 shares” and NaN changes — this appears to be a data/reporting glitch rather than a true change in short positioning, so it is not a reliable market signal right now.
• Negative Sentiment: UBS downgraded HRMY from Buy to Neutral (while raising its price target to $46), a move that reduces near-term buy-side conviction and likely pressured the share price despite the higher target. UBS downgrades Harmony Biosciences Holdings (HRMY)

About Harmony Biosciences

Harmony Biosciences Holdings, Inc is a commercial‐stage biopharmaceutical company focused on developing and delivering therapies for people with rare neurological and endocrine diseases. Founded in 2017 and headquartered in Plymouth Meeting, Pennsylvania, Harmony Biosciences went public in 2020 and trades on the Nasdaq under the ticker HRMY. The company’s mission centers on identifying and advancing medicines that address critical unmet needs in patient populations underserved by existing treatments.

The company’s flagship product is WAKIX (pitolisant), the first and only histamine H3 receptor antagonist/inverse agonist approved by the U.S.